Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

Pancreatic Adenocarcinoma, Version 2.2012

(2017) Margaret A. Tempero et al.   Journal of the National Comprehensive Cancer Network

An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma

(2012) Sarah B. Fisher et al.   CANCER

Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches

(2012) David A. Tuveson et al.   CELL

Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma

(2012) Raphaël Maréchal et al.   GASTROENTEROLOGY

Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine

(2012) Natsuko Kawada et al.   Journal of Hepato-Biliary-Pancreatic Sciences

New biomarkers and targets in pancreatic cancer and their application to treatment

(2012) Eithne Costello et al.   Nature Reviews Gastroenterology & Hepatology

Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection

(2012) Naoya Nakagawa et al.   SURGERY

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel

(2011) J.- L. Van Laethem et al.   ANNALS OF ONCOLOGY

Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer

(2011) Richard Kim et al.   CANCER

Nucleobase Transport by Human Equilibrative Nucleoside Transporter 1 (hENT1)

(2011) Sylvia Y. M. Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy

(2011) Yasuhiro Murata et al.   Journal of Hepato-Biliary-Pancreatic Sciences

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts

(2010) D. Li et al.   CLINICAL CANCER RESEARCH

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

(2010) John P. Neoptolemos et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials

(2009) Marcella Sarzotti-Kelsoe et al.   PLOS MEDICINE

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

(2008) James J. Farrell et al.   GASTROENTEROLOGY

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma

(2008) William F. Regine et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adjuvant Chemoradiation for Pancreatic Cancer: Few Good Data, Much Debate

(2008) Renee Twombly   JNCI-Journal of the National Cancer Institute

Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins

(2008) J. D. Young et al.   XENOBIOTICA